Methods

Patient Population
This was a retrospective study of 394 patients with AMI who were admitted to hospital within 12 h of onset between February 1999 and May 2003. All patients gave informed consent, and the study was approved by the Committee on Human Investigation. There were 58 consecutive patients with AMI complicated by CS. The diagnosis of AMI was made on the basis of the following criteria: (1) chest pain; (2) electrocardiographic ST segment elevation of >0.1 mV in 2 or more limb leads, or >0.2 mV in 2 or more precordial leads, or presentation of left-bundle branch block; and (3) elevated total serum creatine kinase (CK) more than twice the upper limit of the normal range. We excluded 3 patients who had renal failure on admission (defined as serum creatinine concentration >3.0 mg/dl), 4 patients who reached hospital >12 h after onset, 4 patients in whom we could not obtain Thrombolysis in Myocardial Infarction (TIMI) 1 grade-III flow after direct PCI, and 5 patients who died before the initial blood samples were taken. The final study group comprised 42 consecutive patients (27 males, 15 females; mean age 72±11 years, range 49-92). We defined CS as blood pressure <90 mmHg (without inotropic or intraaortic balloon support), signs of hypoperfusion (cold extremities, impaired mental status, or urine output <30 ml/h), and evidence of pulmonary congestion on chest X-ray. Subjects were divided into 2 groups according to the 1-year mortality: those who survived 1 year were group S (n=27), and those who died within the year comprised group D (n=15).
200 mg of ticlopidine, all patients underwent direct PCI within 12 h of the onset of symptoms. In 6 patients, conventional balloon angioplasty was considered sufficient, and the remaining 36 underwent coronary stent implantation. All patients achieved TIMI grade-III flow. For 72 h after reperfusion therapy, patients were given intravenous lidocaine (1 mg/min) and heparin (10,000 units/day). All patients received either an angiotensin-converting enzyme inhibitor (quinapril 5 mg/day) or an angiotensin II receptor blocker (losartan, 50 mg/day).
Blood Sampling
The concentrations of the cardiovascular peptides are reported to peak approximately 24 h after the onset of AMI, 2-4 so we chose that time to take blood samples from all subjects while they were supine. An immuno-radiometric assay (IRMA) was used to measure the adrenomedullin concentration and the concentrations of BNP, ANP, renin, epinephrine, norepinephrine, and aldosterone were all measured in those blood samples. Highly sensitive C-reactive protein (hs-CRP) was evaluated on admission and at 24 h and 48 h after onset. CK was serially determined every 4 h after admission for a period of 3 days and the peak value (peak-CK) was taken to reflect infarct size.
Measurement of Cardiac Function
All subjects underwent left ventriculography in a singleplane with a right anterior oblique of 30°during the acute phase (soon after recanalization) to evaluate the left ventricular (LV) ejection fraction (LVEF) and the LV enddiastolic volume index (LVEDVI), using the area -length method, and to evaluate regional wall motion (RWM), using the center-line method. 5 These data were evaluated by 2 investigators who were unaware of the clinical findings. We excluded posterior infarctions from our evaluation because of associated issues of inaccuracy. We also evaluated the LV end-diastolic pressure (LVEDP). We used the Rentrop classification 6 to evaluate collateral circulation prior to recanalization, and the TIMI classification to evaluate epicardial coronary blood flow. We also monitored major complications, such as cardiac rupture, ventricular arrhythmia (except reperfusion arrhythmia), subacute thrombosis, and acute closure.
Statistical Analysis
Values are expressed as mean ± standard-deviation (SD). All statistical tests were unpaired 2-tailed tests, and a p-value <0.05 was considered statistically significant. The chosen cutoff points for the concentrations of the cardiovascular peptides, peak hs-CRP, and peak-CK were based on tertiles in the overall sample. Multivariate logistic regression analysis was performed, with the independent variables being age, sex, history of myocardial infarction (MI), existence of pre-infarction angina pectoris, spontaneous recanalization, use of respirator, multivessel disease, ventricular arrhythmia, cardiac rupture, cardiopulmonary arrest on arrival, peak-CK value, location of MI, renin, aldosterone, ANP, BNP, epinephrine, norepinephrine, and adrenomedullin. The odds ratios (OR) and 95% confidence intervals (CI) were also calculated.
Results
The clinical characteristics for the 2 groups (group S and group D) are summarized in Table 1 . There were no significant differences in age, gender, coronary risk factors, existence of pre-infarction angina, time since onset to arrival, or history of MI. In other words, the background of both groups of patients was not statistically different. Hemodynamic data at the time of admission and the treatment strategy are shown in Table 2 . There were no significant differences between the 2 groups in the number of patients with cardiopulmonary arrest on arrival (CPAOA), in the heart rate or systolic blood pressure on arrival, or in the rate of use of coronary stents. Also, there were no significant differences in the frequency of use of intra aortic balloon pumping. There were, however, significantly more patients who required a respirator in group D than in group S (87% vs 47%, p<0.01). Acute-phase angiographic results are shown in Table 3 . There were no significant differences between the 2 groups in terms of culprit vessel location, the existence of spontaneous recanalization (TIMI II or III), multivessel disease, or the presence of good collateral circulation (Rentrop grade II or III). Table 4 shows the laboratory findings for the 2 groups. Plasma concentrations of BNP, aldosterone, and adrenomedullin were significantly higher in group D than in group S (BNP: 1270±958 pg/ml vs 436±403 pg/ml, p<0.001; aldosterone: 238±205 pg/ml vs 96±70 pg/ml, p<0.01; adrenomedullin: 13.61±11.39 fmol/L vs 4.74±1.89 fmol/L, p<0.01). Plasma concentrations of ANP, epinephrine, and norepinephrine tended to be higher in group D than in group S. There were no significant differences in peak-CK, renin, or peak hs-CRP between 2 groups.
Major complications in the first 30 days are shown in Table 5 . In terms of clinical severity, there were significantly more patients with ventricular fibrillation in group D than in group S (67% vs 27%, p=0.01). There were no significant differences in the frequency of other complications, such as sub-acute in-stent thrombosis, acute closure, ventricular tachycardia, and cardiac rupture. Table 6 shows LV function in the acute phase (soon after recanalization). There were no significant differences in LVEDP, LVEDVI, RWM, or LVEF; that is, in the acute phase, LV systolic function in these 2 groups of patients did not significantly differ.
Our study population comprised 42 consecutive patients with an AMI and complicated by CS who were admitted within 12 h of onset. The follow-up period for this study was 12 months during which 15 patients died from cardiovascular causes. Pump failure was the cause in 11 and there were 2 cases of cardiac rupture, 1 case of ventricular fibrillation, and 1 case of sudden death out of hospital. The predictors of mortality by multivariate analysis are shown in 
Discussion
In the past 20 years, the mortality rate for AMI patients has been significantly reduced as a result of pharmacological and mechanical reperfusion therapies. Nevertheless, AMI with the complication of CS remains the leading cause of death for these patients. 7 Some reports have suggested that emergency mechanical revascularization improves the survival of patients with CS as compared with initial medical stabilization including thrombolytic treatment. [8] [9] [10] However, at present, the 12-month mortality rate for patients with AMI complicated with CS is still high, at approximately 30-50%, 8, 9, 11 and it remains difficult to predict the clinical prognosis (including mortality) in the early phase.
We have clarified that the useful predictors of mortality in AMI patients with CS are ventricular fibrillation, high peak-CK value and high concentrations of BNP adrenomedullin. Ventricular fibrillation is the most severe arrhythmia, and often occurs in the end stage. The peak-CK value reflects infarct size, so has a close relation to severity in AMI, including mortality. With regard to circulating hormones, we conclude that the concentrations of BNP and adrenomedullin may be reliable predictors of mortality.
The circulating hormones participate in the regulation of cardiovascular system and are closely associated with cardiovascular conditions such as hypertension, LV hypertrophy, and heart failure. BNP, ANP, adrenomedullin, renin, catecholamines, and aldosterone are called cardiovascular peptides and are involved in the neurohumoral activation [12] [13] [14] in patients with AMI and heart failure, their plasma concentrations increasing in proportion to clinical severity. Furthermore, it is known that the concentrations of these cardiovascular peptides in the early phase are closely related to mortality in patients with AMI. Little is known, however, about which of them is most closely related to the mortality rate in AMI complicated by CS.
The cardiovascular peptides have different actions on the cardiovascular system. BNP, 15 ANP 16, 17 and adrenomedullin 18 have protective effects, reducing blood pressure through vasodilation and by decreasing total peripheral resistance, whereas the catecholamines, renin, and aldosterone have the opposite action. 19 Catecholamines are elevated in heart failure, and in the present study we found higher concentrations of epinephrine and norepinephrine in group D than group S. However, they are not a predictor of mortality because not all patients in group D had high concentrations and in fact, the 2 patients who died from cardiac rupture had significantly lower concentrations of catecholamines than the other patients in group D (epinephrine: 252±146 pg/ml vs 3,624±7,421 pg/ml, p<0.05; norepinephrine: 2,084±1,463 ng/ml vs 22,596±41,201 ng/ml, p<0.05). Adrenomedullin was also higher in the 2 dead patients than in the other group D patients, which suggests that adrenomedullin might be a more sensitive predictor of mortality than catecholamines. At present, it is generally recognized that the acutephase plasma concentration of BNP is a useful predictor of the clinical course, including mortality, in AMI. 20, 21 And in the present study, high BNP concentrations seemed to predict cardiac death in AMI with CS according to the results of our multivariate analysis.
From the results of this study, we conclude that the serum concentrations of adrenomedullin and BNP may be reliable predictors of prognosis in AMI complicated by CS. Adrenomedullin has been isolated from not only human pheochromocytoma, but also from the vascular bed and the cardiac ventricles 22 and several of its physiological actions have been documented, such as decreasing total peripheral resistance, and increasing urine flow and sodium excretion. 23 In the setting of AMI, adrenomedullin dilates the pulmonary artery and decreases pulmonary vascular resistance. 24 It has also been reported that plasma adrenomedullin is elevated in AMI patients in proportion to the clinical severity, 25, 26 that adrenomedullin correlates positively with capillary wedge pressure, 2 that it may correlate with the severity of the infarction as well as with patient outcomes in the setting of AMI, 26 that intravenous administration of adrenomedullin may have beneficial effects in terms of improvement of the cardiac index in AMI patients 27 and that adrenomedullin may also have myocardial protective effects during reperfusion following an ischemic episode. Another report has suggested that adrenomedullin possesses defensive properties against the further elevation of peripheral vascular resistance in the setting of heart failure, as opposed to any cardiotoxic effect. 25 Lastly, adrenomedullin may also be an antifibrotic and positive inotrophic factor in the failing heart, suggesting that adrenomedullin may be able to play a compensatory role in the pathophysiology of heart failure. 18 Recently, a study using adrenomedullin to knock out mice reported that adrenomedullin exerted a protective effect against cardiac hypertrophy and fibrosis 28 and had a protective action against the vascular response to injury. 29 Moreover, Okumura et al have reported that adrenomedullin infusion during ischemia/reperfusion attenuated the development of LV remodeling and myocardial fibrosis in rats. 30 These cardioprotective effects of adrenomedullin may be attributed at least partially to its anti-apoptotic effect. 31 In our study, a high concentration of adrenomedullin was identified as an independent predictor of mortality in AMI patients with CS. Adrenomedullin is known to have a cardioprotective effect and to improve heart failure, as well as BNP and ANP. Therefore, they are increased in proportion to the severity of heart failure and therefore elevation of these peptides implies a poor clinical prognosis, including mortality, in AMI.
Study Limitations
The small size of the study population means that our results require confirmation in a large-scale trial before any concrete significance is extrapolated. We excluded patients with renal failure on the basis that they would not be able to tolerate coronary angioplasty, but this may have introduced bias into our results, and we also excluded the patients who died within 24 h of the onset of symptoms and therefore could not provide a blood sample.
Conclusions
From our data, it would appear that the acute-phase plasma concentration of adrenomedullin is a reliable predictor of mortality in patients with AMI complicated by CS and successfully treated by direct PCI, as is the BNP concentration, peak-CK value and ventricular fibrillation.
